Cystic Fibrosis Related Bone Disease: the Role of CFTR

Diagnosis and Treatment of Patients With Cystic Fibrosis

NCT00001223 ·Status: TERMINATED

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

NCT01946412 ·Status: COMPLETED ·Phase: PHASE3

CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis

NCT04206436 ·Status: ACTIVE_NOT_RECRUITING

Energy Balance and Weight Gain With Ivacaftor Treatment

NCT02141464 ·Status: COMPLETED

Tissue Collection From People With Cystic Fibrosis

NCT00015756 ·Status: COMPLETED

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

NCT02742519 ·Status: TERMINATED ·Phase: PHASE3

Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation

NCT02194881 ·Status: COMPLETED

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

NCT01807923 ·Status: COMPLETED ·Phase: PHASE3

Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls

NCT01331980 ·Status: COMPLETED

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

NCT01807949 ·Status: COMPLETED ·Phase: PHASE3

Registry Study on Cystic Fibrosis in Chinese Children

NCT02753374 ·Status: NOT_YET_RECRUITING

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

NCT00909532 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

NCT03068312 ·Status: COMPLETED ·Phase: PHASE3

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT01897233 ·Status: COMPLETED ·Phase: PHASE3

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

NCT02275936 ·Status: COMPLETED ·Phase: PHASE1

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

NCT02797132 ·Status: COMPLETED ·Phase: PHASE3

Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)

NCT02039986 ·Status: COMPLETED

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

NCT01707290 ·Status: COMPLETED ·Phase: PHASE3

IGF-1 Therapy in Patients With Cystic Fibrosis

NCT00566241 ·Status: TERMINATED ·Phase: PHASE1

Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients

NCT00376428 ·Status: TERMINATED ·Phase: PHASE2

Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects

NCT03783286 ·Status: COMPLETED

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

NCT01614457 ·Status: COMPLETED ·Phase: PHASE3

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT03125395 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

NCT03277196 ·Status: COMPLETED ·Phase: PHASE3

Health Outcomes of Parents With Cystic Fibrosis-Aim 2

NCT06296394 ·Status: RECRUITING